` CLN (Celon Pharma SA) vs WIG20 Comparison - Alpha Spread

C
CLN
vs
W
WIG20

Over the past 12 months, CLN has underperformed WIG20, delivering a return of 0% compared to the WIG20's +28% growth.

Stocks Performance
CLN vs WIG20

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CLN vs WIG20

Loading
CLN
WIG20
Difference
www.alphaspread.com

Performance By Year
CLN vs WIG20

Loading
CLN
WIG20
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Celon Pharma SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Celon Pharma SA
Glance View

Market Cap
1.2B PLN
Industry
Pharmaceuticals

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

CLN Intrinsic Value
14.45 PLN
Overvaluation 36%
Intrinsic Value
Price
C
Back to Top